Substituted Pyrazolo[3,4-d]Pyrimidines as Kinase Inhibitors

Abstract

The present disclosure provides compounds of Formula (IA) and/or pharmaceutically acceptable salts thereof that are tyrosine kinase inhibitors, in particular BTK, and are potentially useful for the treatment of diseases treatable by inhibition of tyrosine kinases such as cancer, inflammatory diseases such as arthritis, and the like. Also provided are pharmaceutical compositions containing such compounds and/or pharmaceutically acceptable salts thereof and processes for preparing such compounds and pharmaceutically acceptable salts thereof.

1 - 50 . (canceled) 
     
     
         51 . A method for treating a disease in a patient in recognized need thereof, wherein the disease is selected from the group consisting of hidradenitis suppurativa, aplastic anemia, and scleroderma, comprising administering to the patient in recognized need thereof a pharmaceutical composition comprising a pharmaceutically acceptable excipient and a therapeutically effective amount of a compound selected from the group consisting of: 
       
         
           
           
               
               
           
         
       
       or
 a pharmaceutically acceptable salt of any of the above compounds; or 
 an individual (E)-stereoisomer or (Z)-stereoisomer of any of the above compounds. 
 
     
     
         52 . The method of  claim 51 , wherein the disease is hidradenitis suppurativa. 
     
     
         53 . The method of  claim 51 , wherein the disease is aplastic anemia. 
     
     
         54 . The method of  claim 51 , wherein the disease is scleroderma. 
     
     
         55 . A method for treating a disease in a patient in recognized need thereof, wherein the disease is selected from the group consisting of hidradenitis suppurativa, aplastic anemia, and scleroderma, comprising administering to the patient in recognized need thereof a pharmaceutical composition comprising a pharmaceutically acceptable excipient and a therapeutically effective amount of: 
       
         
           
           
               
               
           
         
       
       or
 a pharmaceutically acceptable salt thereof. 
 
     
     
         56 . The method of  claim 55 , wherein the disease is hidradenitis suppurativa. 
     
     
         57 . The method of  claim 55 , wherein the disease is aplastic anemia. 
     
     
         58 . The method of  claim 55 , wherein the disease is scleroderma.